Lakefront Biotherapeutics

Lakefront Biotherapeutics

Yahoo Finance • 7 days ago

Acquisition of Own Shares

Lakefront Biotherapeutics Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront... Full story

Yahoo Finance • 19 days ago

Lakefront Receives Transparency Notification from Bank of America

Lakefront Receives Transparency Notification from Bank of America·globenewswire.com Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency noti... Full story

Yahoo Finance • last month

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • last month

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Key Points Interested in Lakefront Biotherapeutics American Depositary Shares? Here are five stocks we like better. Lakefront plans to start registrational trials for gamgertamig in ITP and AIHA in 2027, with additional autoimmune basket... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthu... Full story

Yahoo Finance • 5 months ago

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announcedthat Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company’s strategi... Full story

Yahoo Finance • 5 months ago

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET – Gilead Sciences, Inc. (N... Full story

Yahoo Finance • 5 months ago

GILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN

Bedrijven gaan samenwerken aan de ontwikkeling van gamgertamig, een potentieel first-in-class en best-in-class T-cel-engager voor auto-immuunziekten Foster City, Californië en Mechelen, België; 4 juni 2026, 22.15 CET –Gilead Sciences, Inc... Full story

Yahoo Finance • 5 months ago

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – FOSTER CITY, Calif. & MECHELEN, Belgium, June 04, 2026--(BUSINESS WIRE)--Gilead Sciences,... Full story

Yahoo Finance • 6 months ago

Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Lakefront Biotherapeutics NV (AMS:LKFT) last week reported its latest quarterly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. Revenues fell badly short of expe... Full story